Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
Compose a Response to This Article
Other responses
No responses have been published for this article.
